Autologous transplantation in chronic myelogenous leukemia: European results: Chronic Leukemia Working Party of the EBMT.
Autologous stem cell transplantation (ASCT) was performed in 95 patients with chronic myelogenous leukemia (CML) in chronic phase and their data were reported to the European Bone Marrow Transplant Registry. Most patients presented bad prognostic factors. The results were analysed by September 1, 1993. The actuarial proportion of patients who achieved a complete hematological response at one year was 87.3+/-7.5% (95% CI). The 3-year percentage of major cytogenetic response was 38.6+/--13% (95% CI). The actuarial risk of transformation for the evaluable patients was 31.5+/-14% (95% CI) and the actuarial survival at four years was 83.3+/-10% (95% CI). These encouraging results suggest that ASCT by itself could play a role to prolong survival in CML patients.
Reiffers
J
J
Bone Marrow Transplant Unit, CHRBordeaux Hôpital, Pessac, France.
Goldman
J
J
Meloni
G
G
Cahn
J Y
JY
Faberes
C
C
Apperley
J
J
D000293:Adolescent; D000328:Adult; D002648:Child; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000235:genetics / Q000628:therapy*; D008875:Middle Aged; D015996:Survival Rate; D014182:Transplantation, Autologous